Product Description
AKR1C3 inhibitor for Endometriosis
Mechanisms of Action: AKR1C3 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Bayer
Company Location:
Company Founding Year: 1863
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Endometriosis
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02434640 |
NCT02434640 | P1 |
Completed |
Endometriosis |
2015-12-01 |
2019-03-20 |
Treatments |
|
2017-000244-18 |
Akrendo 1 | P2 |
Terminated |
Endometriosis |
2018-10-22 |
2022-03-13 |
Treatments |
|
NCT03373422 |
AKRENDO1 | P2 |
Terminated |
Endometriosis |
2018-07-23 |
2019-03-21 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|